- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MOLECURE Aktie jetzt für 0€ handeln | |||||
| 28.03. | Strategic update on the progress and development of Molecure's key clinical projects in 2024 | 151 | GlobeNewswire (Europe) | Molecure achieved key milestones in the development of its innovative therapies in 2024 and plans to accelerate research and development in its most advanced clinical programs: OATD-01 and OATD-02.... ► Artikel lesen | |
| 15.10.24 | Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors. | 269 | GlobeNewswire (Europe) | This license covers first-in-class small molecule YKL-40 inhibitors, including the lead molecule OAT-3912, which has shown potential therapeutic benefits in preclinical models in various cancers as... ► Artikel lesen | |
| 31.07.24 | Avicenna Biosciences, Inc.: Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs | 462 | Business Wire | Molecure S.A. ('Molecure', SWE Ticker: MOC) and Avicenna Biosciences, Inc. announced today that they have entered into a strategic research collaboration to facilitate the discovery and development... ► Artikel lesen |
3 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CO.DON | 0,029 | +7,41 % | CO.DON GmbH ist Partner des EU-geförderten Projekts zur Weiterentwicklung des 3D-Bioprinting für die Geweberegeneration | Teltow (ots) - Das im Dezember 2024 gestartete EU-geförderte Projekt micro2MACRO (m2M) zielt darauf ab, die Geweberegeneration durch eine innovative Bioprinting-Plattform voranzutreiben. m2M konzentriert... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,465 | +0,48 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Pricing of $23.0 Million Underwritten Offering | Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants... ► Artikel lesen | |
| IMMATICS | 5,300 | +1,34 % | Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing... ► Artikel lesen | |
| ALDEYRA | 2,301 | -1,24 % | Hagens Berman Sobol Shapiro LLP: Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter - Hagens Berman | SAN FRANCISCO, April 10, 2025 /PRNewswire/ -- On April 3, 2025 investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) saw the price of their shares crash over... ► Artikel lesen | |
| MEDIFAST | 10,940 | -1,75 % | Medifast meldet erneuten Umsatzcrash: Q1 2025 mit 33,8?% Rückgang auf 115,7 Mio. US-Dollar | ||
| PHARMING | 1,038 | +0,29 % | Pharming Group N.V.: Pharming Group to participate in June investor conferences | Leiden, the Netherlands, May 28, 2025: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming's management will participate in the following investor conferences... ► Artikel lesen | |
| COHERUS ONCOLOGY | 0,738 | +2,08 % | Coherus BioSciences, Inc. (CHRS): A Bull Case Theory | ||
| ORUKA THERAPEUTICS | 10,300 | -7,21 % | Oruka Therapeutics, Inc. - 8-K, Current Report | ||
| INNOVIVA | 19,000 | 0,00 % | Basilea Pharmaceutica AG: Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera (Ceftobiprol) in den Vereinigten Staaten bekannt | Ad hoc-Mitteilung gemäss Art. 53 KR
Allschwil, 16. Dezember 2024
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem... ► Artikel lesen | |
| DBV TECHNOLOGIES | 1,532 | +2,96 % | DBV Technologies S.A.: Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025 | Information regarding the total number of voting rights and total number of shares of the Company as of May 30, 2025
(Article 223-16 of the... ► Artikel lesen | |
| ARMATA PHARMACEUTICALS | 1,610 | -1,23 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia | All primary endpoints for safety, tolerability, and clinical response in the intent-to-treat population met
AP-SA02 arm significantly improved clinical outcomes... ► Artikel lesen | |
| BRAINSTORM CELL THERAPEUTICS | 0,990 | -100,00 % | BrainStorm Cell Therapeutics Inc.: BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn for ALS | Investor call and webcast scheduled for today at 8:30 a.m. ET
NEW YORK, May 19, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,010 | +2,21 % | Dividendenbekanntmachungen (15.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 1&1 AG DE0005545503 - 0,05 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0536 EUR ADMIRAL GROUP PLC GB00B02J6398 0,914 GBP 1,0846... ► Artikel lesen | |
| LIQUIDIA | 16,110 | +1,26 % | Liquidia auf der Jefferies-Konferenz: Strategische Schritte im PAH-Markt | ||
| Q32 BIO | 1,780 | +7,23 % | Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update | -- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 --
-- First patient dosed in SIGNAL-AA Part A open-label extension (OLE)... ► Artikel lesen |
MOLECURE SA gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,14 % bei einem Aktienkurs von 1,412 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MOLECURE SA finden Sie auf Wallstreet Online.